{
    "clinical_study": {
        "@rank": "85542", 
        "arm_group": [
            {
                "arm_group_label": "Colistin and Meropenem", 
                "arm_group_type": "Experimental", 
                "description": "IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function"
            }, 
            {
                "arm_group_label": "Colistin", 
                "arm_group_type": "Active Comparator", 
                "description": "IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the addition of meropenem to colistin is\n      better than colistin alone in the treatment of clinically significant infections caused by\n      multi-drug resistant bacteria"
        }, 
        "brief_title": "Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gram-Negative Bacterial Infections", 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Gram-Negative Bacterial Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult inpatients\n\n          -  Clinically significant, microbiological-documented infection caused by\n             carbapenem-resistant and colistin-susceptible Gram-negative bacteria and identified\n             according to CDC criteria- blood stream infections, hospital acquired pneumonia,\n             ventilator associated pneumonia, and urinary tract infections\n\n          -  Patient recruitment will occur only after microbiological documentation and\n             susceptibility testing. Patients will be included within 96 hours of the time the\n             index culture was taken (typically within 48 hours of isolate identification),\n             regardless of the antibiotic treatment administered during this time period.\n\n        Exclusion Criteria:\n\n          -  Previous inclusion in the trial. Patients will be included in the RCT only once for\n             the first identified episode of infection\n\n          -  Pregnant women\n\n          -  Epilepsy or prior seizures\n\n          -  Known allergy to colistin or a carbapenem"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732250", 
            "org_study_id": "0276-12-RMC"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Colistin and Meropenem", 
                    "Colistin"
                ], 
                "description": "IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.", 
                "intervention_name": "Colistin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Colistimethate Sodium", 
                    "Coliracin"
                ]
            }, 
            {
                "arm_group_label": "Colistin and Meropenem", 
                "description": "IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.", 
                "intervention_name": "Meropenem", 
                "intervention_type": "Drug", 
                "other_name": "Meronem"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Colistin", 
                "Meropenem"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gram-Negative Bacterial Infections", 
            "Resistant Bacteria", 
            "Drug Resistance, Bacterial", 
            "Colistin"
        ], 
        "lastchanged_date": "October 6, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Diamantis Plachouras, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Atikkon Hospital"
                }, 
                "investigator": {
                    "last_name": "Diamantis Plachouras, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Diamantis Plachouras, MD PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Laikon Hosptial"
                }, 
                "investigator": {
                    "last_name": "Diamantis Plachouras, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mical Paul, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel"
                    }, 
                    "name": "Rambam Health Care Center"
                }, 
                "investigator": {
                    "last_name": "Mical Paul, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Leonard Leibovici, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Petach-Tikvah", 
                        "country": "Israel"
                    }, 
                    "name": "Rabin Medical Center"
                }, 
                "investigator": {
                    "last_name": "Leonard Leibovici, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yehuda Carmeli, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel-Aviv", 
                        "country": "Israel"
                    }, 
                    "name": "Tel-Aviv Sourasky Medical Center"
                }, 
                "investigator": {
                    "last_name": "Yehuda Carmeli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "Agostino Gemelli Hospital"
                }, 
                "status": "Terminated"
            }
        ], 
        "location_countries": {
            "country": [
                "Greece", 
                "Israel", 
                "Italy"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem", 
        "overall_contact": {
            "email": "paulm@post.tau.ac.il", 
            "last_name": "Mical Paul, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Radboud University", 
                "last_name": "Johan Mouton, MD PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Rambam Health Care Centre", 
                "last_name": "Mical Paul, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Israel: Ethics Commission", 
                "Greece: Ethics Committee", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as a composite of all of the following, all measured at 14 days:\nPatient alive\nSystolic blood pressure >90 mmHg without need for vasopressor support\nStable or improved SOFA score, define as:\nfor baseline SOFA \u2265 3: a decrease of at least 30%;\nfor baseline SOFA <3: stable or decreased SOFA score\nFor patients with HAP/ VAP, PaO2/FiO2 ratio stable or improved\nFor patients with bacteremia, no growth of the initial isolate in blood cultures taken on day 14 if patient still febrile", 
            "measure": "Clinical success", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732250"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rabin Medical Center", 
            "investigator_full_name": "Mical Paul", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "14 and 28-day all-cause mortality.\nIf patients are discharged or death occurs before end of follow-up (day 28), we will end data collection at that date. We will attempt to determine survival status at day 28 for all patients (central registry in Israel; re-admissions, rehabilitation centers, hospital transfers in Greece and Italy).", 
                "measure": "Secondary outcomes and adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "14 and 28 days"
            }, 
            {
                "description": "Clinical success, but with modification to the antibiotic treatment not permitted by protocol", 
                "measure": "Clinical success with modification", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "defined as time to reach a temperature of <38\u00b0C with no recurrence for 3 days", 
                "measure": "Time to defervescence", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Time to weaning from mechanical ventilation in VAP for patients weaned alive", 
                "measure": "Time to weaning", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Time to hospital discharge for patient discharged alive", 
                "measure": "Time to hospital discharge", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Microbiological failure, defined as isolation of the initial isolate (phenotypically identical) in a clinical sample (blood or other) 7 days or more after start of treatment or its identification in respiratory samples.\nFor all patients with VAP/ HAP sputum or tracheal aspirates will be obtained on day 7, regardless of clinical response\nFor all patients with UTI, a repeat urine culture will be obtained on day 7, regardless of clinical response\nFor patients with bacteremia, blood cultures will be repeated on day 7 and 14, only if the patient is febrile at that time", 
                "measure": "Microbiological failure", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Defined as a new clinically or microbiologically-documented infections by CDC criteria within 28 days", 
                "measure": "Superinfections", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Colonization or infection by newly-acquired (other species than the initial infection) carbapenem-resistant or colistin-resistant Gram-negative bacteria. Colonization will be assessed by rectal surveillance", 
                "measure": "New resistant infection", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Clostridium-difficile-associated diarrhea, defined by diarrhea with a positive C. difficile toxin test", 
                "measure": "CDAD", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Rabin Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "European Commission", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mical Paul", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}